1,024
Views
0
CrossRef citations to date
0
Altmetric
Articles

Rising prescription stimulant poisoning in Australia: a retrospective case series

ORCID Icon, , & ORCID Icon
Article: 2174689 | Received 29 Jun 2022, Accepted 25 Jun 2023, Published online: 13 Feb 2023

References

  • Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res. 1998;94(1):1–7.
  • Pharmaceutical Benefits Scheme. Attention deficit hyperactivity disorder: utilisation analysis. Canberra: Commonwealth of Australia; 2021 [cited 16 Nov 2022]. Available from: https://www.pbs.gov.au/industry/listing/participants/public-release-docs/2018-05/adhd-dusc-prd-2018-05-final.pdf
  • Steer C, Froelich J, Soutullo CA, et al. Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder. CNS Drugs. 2012;26(8):691–705.
  • WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2023. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2022.
  • WHO Collaborating Centre for Drug Statistics Methodology. Centrally acting sympathomimetics. [Internet]. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2022. [cited 2022 Dec 26]. Available from: https://www.whocc.no/atc_ddd_index/?code=N06BA&showdescription=no
  • Heal DJ, Smith SL, Gosden J, et al. Amphetamine, past and present–a pharmacological and clinical perspective. J Psychopharmacol. 2013;27(6):479–496.
  • Wong YN, Wang L, Hartman L, et al. Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers. J Clin Pharmacol. 1998;38(10):971–978.
  • Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet. 1999;37(6):457–470.
  • Markowitz JS, Straughn AB, Patrick KS, et al. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet. 2003;42(4):393–401.
  • Kaland ME, Klein-Schwartz W. Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centres. Clin Toxicol (Phila). 2015;53(5):477–485.
  • Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry. 2018;5(10):824–835.
  • Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry. 2010;10:Article 67.
  • Sembower MA, Ertischek MD, Buchholtz C, et al. Surveillance of diversion and nonmedical use of extended-release prescription amphetamine and oral methylphenidate in the United States. J Addict Dis. 2013;32(1):26–38.
  • Fry M, Harris K, Isoardi KZ. Falling methamphetamine-related presentations to a clinical toxicology unit during the COVID-19 pandemic. Emerg Med Australas. 2021;33(1):179–180.
  • Mitchell P. Australia’s illegal drug supply down, prices up as pandemic hits cartels. 2020 [Cited 19 Aug 2020]. Available from URL: https://indaily.com.au/news/2020/06/09/australias-illegal-drug-supply-down-prices-up-as-pandemic-hits-cartels/.
  • Thygesen K, Alpert JS, Jaffe AS, Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018;72(18):2231–2264. Epub 2018 Aug 25. PMID: 30153967.
  • Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–84.
  • Pottel H, Hoste L, Dubourg L, et al. An estimated glomerular filtration rate equation for the full age spectrum. Nephrol Dial Transplant. 2016;31(5):798–806.
  • Braun C, Fazlur Rahman AKM, Macomb E, et al. Derivation and evaluation of baseline creatinine equations for hospitalized children and adolescents: the AKI baseline creatinine equation. Pediatr Nephrol. 2022;37(12):3223–3233.
  • Persson HE, Sjöberg GK, Haines JA, et al. Poisoning severity score: grading of acute poisoning. J Toxicol Clin Toxicol. 1998;36(3):205–213.
  • Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. 2009;23(4):419–427.
  • Dolder PC, Strajhar P, Vizeli P, et al. Pharmacokinetics and pharmacodynamics of lisdexamfetamine compared with D-amphetamine in healthy subjects. Front Pharmacol. 2017;8:Article 617.
  • Janowsky DS, Davis JM. Methylphenidate, dextroamphetamine, and levamfetamine: effects on schizophrenic symptoms. Arch Gen Psychiatry. 1976;33(3):304–308.
  • Jensen LS, Pagsberg AK, Dalhoff K. Methylphenidate misuse in adult patients and the impact of therapeutic use. Hum Exp Toxciol. 2015;34:460–467.
  • Cairns R, Daniels B, Wood DA, et al. ADHD medication overdose and misuse: the NSW Poisons Information Centre experience, 2004-2014. Med J Aust. 2016;204(4):154. Article 154.
  • Bentur Y, Lurie Y, Tamir A, et al. Reliability of history of acetaminophen ingestion in intentional drug overdose patients. Hum Exp Toxicol. 2011;30(1):44–50. Epub 2010 Mar 30. PMID: 20354060.